Glaxo Pays Up | GenomeWeb

Glaxo Pays Up

GlaxoSmithKline has agreed to pay $750 million to settle several lawsuits stemming from whistleblower complaints about the company knowingly selling contaminated baby ointment and an ineffective antidepressant, report the New York Times' Gardiner Harris and Duff Wilson. Glaxo sold 20 drugs — including antidepressant Paxil, diabetes drug Avandia, and heart drug Coreg — manufactured at a plant that had contamination problems for many years, Gardiner and Wilson say.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.